Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation

Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation

Abstract Background Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53. MDM2 ubiquitination of p53 facilitates its XPO1-mediated nuclear export, thus limiting p53 tumo...

Full description

Bibliographic Details
Main Authors: Valentina Zuco, Sandro Pasquali, Monica Tortoreto, Silvia Brich, Stefano Percio, Gian Paolo Dagrada, Chiara Colombo, Roberta Sanfilippo, Calogero Lauricella, Mrinal Gounder, Rihan El Bezawy, Marta Barisella, Angelo Paolo Dei Tos, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti, Nadia Zaffaroni
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Dedifferentiated liposarcoma
PDX
Primary cell culture
XPO1
Selinexor
Doxorubicin
Online Access:https://doi.org/10.1186/s13046-021-01886-x

Internet

https://doi.org/10.1186/s13046-021-01886-x

Similar Items